Study of Drug Interactions in COVID-19 Patients with Type 2 Diabetes Mellitus at The General Hospital in South Tangerang City Period 2021 Yusroh Umami*, Nurmeilis*, Nurhaida M**
*Department of Pharmacy, Faculty of Health Sciences, UIN Syarif, Jakarta, Indonesia
**General Hospital in South Tangerang City, Indonesia
Abstract
At the beginning of 2020, the world reported the presence of a new type variant of the coronavirus called Coronavirus Disease 2019 caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). Diabetes mellitus is one of the common comorbidities found in COVID-19 patients. The use of large amounts of medication (polypharmacy) in COVID-19 patients with comorbid diabetes mellitus can increase the possibility of drug interactions. This study aims to determine the potential drug-drug interactions and the relationship between drug interactions and clinical outcomes in COVID-19 patients with comorbid type 2 diabetes mellitus at the General Hospital in South Tangerang City. This study is a retrospective conducted in the hospital by using patients admitted from January-December 2021. Potential drug-drug interaction was analyzed by using Lex-Interact, software, Medscape, and drugs.com. The 97 patients meet the inclusion and exclusion criteria. The result of the study found that 40 patients who experienced drug interactions with COVID-19 drug and antidiabetics (20.31%), the majority of them are in moderate severity-degree (78.5%), mayor severity-degree (21.5%), with pharmacodynamic mechanism (100%). And there is no significant relationship between drug interactions and clinical outcomes of patients (P> 0.05).
Keywords: Drug Interactions, coronavirus disease 2019, type 2 diabetes mellitus, clinical outcomes
